Oxford Finance LLC

Oxford’s Enterprise Lending Team is pleased to announce the extension of?Scholar Rock?debt facility, with $50 million funded at close to maintain the current balance and up to $150 million of additional availability.?Scholar?Rock?is advancing apitegromab in spinal muscular atrophy, a rare genetic disorder characterized by the progressive atrophy of muscles, which affects an estimated 35,000 patients in the U.S. and Europe. Proceeds from the financing will support the advancement of apitegromab and?Scholar?Rock’s other pipeline assets.

Oxford’s Real Estate & ABL Team is pleased to announce the successful closing of a $256,850,000 senior credit facility for an existing borrower in California. Proceeds were primarily used to refinance four skilled nursing facilities and acquire 13 skilled nursing facilities across the state. Thanks to Oxford’s efficient underwriting process and strong relationship with the borrower, the transaction closed just 20 days after term sheets were signed.

Oxford’s Leveraged Lending Team is pleased to announce the closing of a senior credit facility with?Horizon Infusions, in support of its partnership with?Rubicon Founders.?Horizon Infusions is Ohio’s largest network of infusion centers, committed to delivering expert care in a low-cost patient-focused environment.

Oxford Finance is pleased to sponsor BHASe Summit on February 12-14, 2025. We look forward to meeting you there to talk about financing for your transaction. Please reach out to Kevin Harbour, Richard Russakoff or Katherine Thornett to connect with us.

Oxford Finance is pleased to sponsor eCap Summit on February 10-12, 2025. We look forward to meeting you there to talk about financing for your transaction. Please reach out to Kevin Harbour, Richard Russakoff or Katherine Thornett to connect with us.

Oxford’s Enterprise Lending Team is delighted to announce the closing of a debt financing agreement for up to $150 million with Inhibrx Biosciences, Inc. Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company’s current clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what Inhibrx believes to be the most appropriate agonist function. Proceeds from the financing will provide flexibility post data readouts expected later this year for INBRX-109 and INBRX-106 programs. Link to Press Release: https://lnkd.in/dhhxxWTX

Oxford’s Enterprise Lending Team is pleased to announce the closing of a debt financing agreement for up to $200 million with Soleno Therapeutics, Inc. Soleno is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. An NDA for its lead product candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome in individuals four years and older who have hyperphagia, is currently under review by the FDA and was granted Priority Review. Proceeds from the financing will be used to strengthen Soleno’s financial position and provide additional support for anticipated commercial launch activities.

Oxford’s Leveraged Lending Team is pleased to announce the closing of a senior credit facility with?Enjoin, LLC, in support of its partnership with 3 Boomerang Capital.? ? Founded in 1988 by?Garry L. Huff, MD, CCS, Enjoin is a physician-directed partner in the mid-revenue cycle to many of the country’s leading health systems.

Oxford’s Enterprise Lending Team proudly announces the closing of a debt financing agreement for up to $275 million with Orthofix Medical Inc. Orthofix is a global medical technology company that offers a comprehensive portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics, and enabling technologies, including the 7D FLASH? navigation system, that heal musculoskeletal pathologies. Proceeds from the financing will be used to refinance Orthofix’s existing debt facility and to support long-term, profitable growth. Link to Press Release: https://lnkd.in/eSK6VnxA